Since lowering systemic risk factors can only prevent 35% of cardiovascular events, novel interventions are needed. Two approaches are being pursued:
1. Directly increasing vessel-wall resistance against atherogenic insults.
2. Identifying inflammation-modulating pathways to attenuate atherogenesis

With respect to the first, efforts are being made to target the endothelial glycocalyx as therapeutic target.

With respect to the second, HDL-increasing agents are being evaluated as novel targets to attenuate pro-inflammatory changes.

Themes: Metabolic Disorders, Cardiovascular Diseases
Effective start/end date01/01/2006 → …

ID: 177436